...
首页> 外文期刊>European journal of clinical pharmacology >Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
【24h】

Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.

机译:洛匹那韦与以利福平为基础的抗结核药物联合治疗在艾滋病毒感染的南非儿童中的群体药代动力学。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: the population pharmacokinetics (PK) of lopinavir in tuberculosis (TB)/human immunodeficiency virus (HIV) co-infected South African children taking super-boosted lopinavir (lopinavir/ritonavir ratio 1:1) as part of antiretroviral treatment in the presence of rifampicin were compared with the population PK of lopinavir in HIV-infected South African children taking standard doses of lopinavir/ritonavir (ratio 4:1). METHODS: lopinavir concentrations were measured in 15 TB/HIV-co-infected paediatric patients who were sampled during and after rifampicin-based TB treatment and in 15 HIV-infected children without TB. During TB therapy, the dose of ritonavir was increased to lopinavir/ritonavir 1:1 in order to compensate for the induction of rifampicin. The children received median (interquartile range=IQR) doses of lopinavir 292 mg/m(2) (274, 309) and ritonavir 301 mg/m(2) (286, 309) twice daily. After TB treatment completion the children received standard doses of lopinavir/ritonavir 4:1 (median [IQR] lopinavir dose 289 mg/m(2) [286, 303] twice daily) as did those without TB (median [IQR] lopinavir dose 265 mg/m(2) [249, 289] twice daily). RESULTS: lopinavir oral clearance (CL/F) was about 30% lower in children without TB than in co-infected children treated with super-boosted lopinavir. However, the predicted lopinavir C(min) was above the recommended minimum therapeutic concentration during TB/HIV co-treatment in the 15 children. Lopinavir CL/F increased linearly during the dosing interval. CONCLUSIONS: increasing the ritonavir dose to achieve a lopinavir/ritonavir ratio of 1:1 when given in combination with rifampicin-based TB treatment did not completely compensate for the enhancement of lopinavir CL/F caused by rifampicin. The time-dependent lopinavir CL/F might be due to a time-dependent recovery from ritonavir inhibition of lopinavir metabolism during the dosing interval.
机译:目的:罗非那韦在结核病(TB)/人类免疫缺陷病毒(HIV)中的人群药代动力学(PK)共同感染南非儿童,他们将超级罗非那韦(lopinavir / ritonavir比例为1:1)作为抗逆转录病毒治疗的一部分将利福平的药敏剂量与标准剂量的洛匹那韦/利托那韦(比例4:1)的感染HIV的南非儿童中的洛匹那韦的PK人群进行比较。方法:对以利福平为基础的结核病治疗期间和之后抽取的15 TB / HIV合并感染的儿科患者和15例无TB的HIV感染儿童进行了洛匹那韦浓度的测量。在结核病治疗期间,将利托那韦的剂量增加至洛匹那韦/利托那韦1:1,以补偿利福平的诱导。这些孩子每天两次接受洛匹那韦292 mg / m(2)(274,309)和利托那韦301 mg / m(2)(286,309)的中位剂量(四分位间距= IQR)。结核病治疗完成后,儿童接受标准剂量的洛匹那韦/利托那韦4:1(中位[IQR]洛匹那韦剂量289 mg / m(2)[286,303]每天两次)与无结核病的孩子(中位[IQR]洛匹那韦剂量每天两次,每次265 mg / m(2)[249,289]。结果:无结核病患儿的洛匹那韦口服清除率(CL / F)比用超级强化洛匹那韦治疗的合并感染儿童低约30%。但是,在15名儿童的TB / HIV联合治疗期间,预测的lopinavir C(min)高于建议的最低治疗浓度。在给药间隔期间,洛匹那韦CL / F线性增加。结论:与基于利福平的结核病治疗联用时,增加利托那韦剂量使洛匹那韦/利托那韦的比例达到1:1并不能完全弥补利福平引起的洛匹那韦CL / F的增加。时间依赖的洛匹那韦CL / F可能是由于给药间隔期间利托那韦抑制洛匹那韦代谢的时间依赖性恢复所致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号